Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01667926 · ClinicalTrials.gov registry record · NA
Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT01667926: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01667926 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01667926, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients. The results of the study could lead to development of new strategies for treating depression.
Interventions
- DRUG Placebo
- DRUG Ketamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2013-01 |
| Est. Completion | 2015-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01667926
The ClinicalTrials.gov registry entry for NCT01667926 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01667926 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01667926 about?
NCT01667926 is a clinical study titled "Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder". Ketamine infusions resulted in an acute reduction in global depression scores and in severity of suicidal ideation. The investigators therefore plan to investigate the feasibility and efficacy of repeated intravenous administration of ketamine in severely depressed, treatment resistant patients. The...
What is the current status of trial NCT01667926?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2013-01. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01667926?
The interventions under investigation include: Placebo (DRUG), Ketamine (DRUG).
Who is sponsoring clinical trial NCT01667926?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.